Kodiak Sciences Inc.
KSI-101
macular edema secondary to inflammation (MESI)
Countdown
86days
Phase 1 readout · ~ Sep 30, 2026 estimated
What's at stake
Phase 1 trial results for KSI-101 in macular edema secondary to inflammation (MESI) are due ~ Sep 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 12h ago
“expected 4Q2026, if successful”